The Advancement of Medical Biotechnology in Developing Countries: Economic Opportunities and Challenges
DOI:
https://doi.org/10.54097/45c92q28Keywords:
Medical biotechnology; value-based healthcare; developing countries.Abstract
Starting from decades ago, medical biotechnology has revolutionized the healthcare industry by offering new hopes for previously untreatable diseases and improving overall health outcomes. To explore the advancements in medical biotechnology, this research essay begins by introducing several examples of medical biotechnologies that are currently in progress of advancement, including CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats), Recombinant DNA technology, and Stem Cell Research. Then, it delves into the developments of medical biotechnology in developing countries and examines the opportunities and challenges faced during its progress. The medical biotechnology industry in most developing countries is relatively immature, so new opportunities appear as improving health outcomes and driving economic growth. Nevertheless, the development and adoption of medical biotechnology in developing countries are under different levels of financial burdens, so supports and collaborations on research and development from the healthcare leaders are essential. Finally, this research essay offers some suggestions to the cost reduction strategies of medical biotechnology in developing countries by promoting the hypothetical combination of value-based healthcare and modern monetary theory.
Downloads
References
Bhatia S, Goli D. Introduction to pharmaceutical biotechnology. Institute of Physics (Great Britain), 2018, 1: 1-61.
Khan S, Ullah M.W, Siddique R, et al. Role of recombinant DNA technology to improve life. International Journal of Genomics, 2016, 2: 1-14.
Zhang D, Hussain A, Manghwar H, et al. Genome editing with the CRISPR‐Cas system: an art, ethics and global regulatory perspective. Plant Biotechnology Journal, 2020, 18(8): 1651-1669.
Bartkowski B, Theesfeld I, Pirscher F, et al. Snipping around for food: Economic, ethical and policy implications of CRISPR/Cas genome editing. Geoforum, 2018, 96: 172-180.
Barh D, Azevedo V. Omics technologies and bio-engineering. New York: Academic Press. 2017.
Genetic Screening. Encyclopedia of applied ethics (second edition). New York: Academic Press, 2012.
Lane R. Sarah Gilbert: carving a path towards a COVID-19 vaccine. The Lancet, 2020, 395(10232): 1247.
Davis J.C, Furstenthal L, Desai A.A, et al. The microeconomics of personalized medicine: today’s challenge and tomorrow’s promise. Nature Reviews Drug Discovery, 2009, 8(4): 279-286.
Ecuru J, Naluyima H. Biotechnology developments in Uganda and associated challenges. African Crop Science Journal, 2010, 18(4): 133-139.
Muraskin W. The global alliance for vaccines and immunization: is it a new model for effective public–private cooperation in international public health? American Journal of Public Health, 2004, 94(11): 1922-1925.
Bathurst I, Hentschel C. Medicines for malaria venture: sustaining antimalarial drug development. Trends in Parasitology, 2006, 22(7): 301-307.
McMaughan D.J, Oloruntoba O, Smith M.L. Socioeconomic status and access to healthcare: Interrelated drivers for healthy aging. Frontiers in Public Health, 2020, 8: 00231.
Putera, I. Redefining health: implication for value-based healthcare reform. Cureus, 2017, 9(2): 1067.
Pandit J.J. Modern monetary theory for the post-pandemic NHS: why budget deficits do not matter. British Journal of Healthcare Management, 2022, 28(1): 37-46.
Kelton S. The deficit myth: modern monetary theory and the birth of the people's economy. New York: Public Affairs. 2020.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
